AGENDA for the June Nicotine Conference
(6-8th June 1984)
Wednesday 6 June
0900-0915 Introduction - including re-cap on aims
C. I. Ayres
(Chairman)
Session I Nicotine dose requirements - background
0915-1015 (a) A smokers requirement for nicotine.
GR&DC
A smoking behaviour and market place view. ITL
Delegates
1015-1055 (b) Product elasticity, nicotine and
perception of product strength. BAT Hamburg
1055-1115 Group discussions
Session II Nicotine dose estimation
1115-1215 (a) Human nicotine pharmacokinetics
GR&DC
B&W
1215-1300 (b) Relevance of nicotine/cotinine GROC
measurements in body fluids. B&W
1415-1445 (c) Nicotine retention during inhalation
and its quantification GR&DC
1445-1505 Group discussions
Session III Effects of nicotine - sensory
/psychological considerations
1505-1525 (a) Sensory properties of nicotine GR&DC
1525-1555 (b) Relationship between
ionised/un-ioni-;:,ed
nicotine and product attributes. BAT Hamburg
1555-1640 (c) P~.-ychological aspects of smoking
(Gale approach) GR&DC
1640-1700 Group discussions
4 ~-
cr"
CXD
BATCO document for Province of BritiSh Columbia 5
November 1999


NICOTINE CONFERENCE NOTES
WEDNESDAY
Session I Nicotine dose requirement - Background
It is a commonly held view that smokers smoke, at
least
in part, for nicotine. To attempt to examine this
hypothesis,
are there any market place trends or observations
in products
for which there have been reductions in nicotine
levels that
can support or refute this view. Reductions in
product
deliveries have consistently shown a trend of an
increase in
smoking behaviour parameters. What aspects of
smoking
behaviour research or product design
characteristics indicate
that nicotine is the influencing or controlling
factor?
The primary objectives of the presentations and
group
discussion:
1. Examine the empirical market place or smoking
behaviour
observations that indicate or implicate nicotine
as a
controlling or influencing factor in product
acceptance.
2. Review the research to establish the
relationship between
tar and nicotine (ratios and absolute levels) as
controlling factors of smoking behaviour and their
role
in product assessment and acceptance. .1
3. Identify to what extent the nicotine dose on a
puff-by-
puff, per cigarette, or on a daily basis can be
used to
indicate a smokers requirement for nicotine or
infer
product acceptance.
c0
BATCo document for Province of British Columbia 5
November 1999


-2-
WEDNESDAY
Session II Nicotine dose estimation
Considerable controversy exists regarding the
ability to
quantify the whole body dose of nicotine. The
objective of
this session must be to critically review the
literature and
available data on nicotine pharmacokinetics and
nicotine dose
estimation generally. The purpose of these
presentations
will be to examine the ability to quantify
nicotine intake
and to assess the significance of these findings
for smoking
behaviour, cigarette design and product
development.
The primary objectives of the presentations and
group
discussions:
1. To determine if sufficient information exists
to estimate
nicotine.uptake from plasma cotinine levels.
2. Identify the implication and relevance of these
measures
for product design in relation to a smokers
requirement
for nicotine.
3. Indicate and identify research required to
determine the
site of nicotine uptake and assess its relevance
to
product acceptability.
4. Localised high concentrations and specific
tissue levels
of nicotine can have marked effects on-the
physiological
and pharmacological responses. Is it technically
feasible
to determine and quantify the differential
distribution
of nicotine.
BATCo document for Province of British Columbia 5
November 1999


-3-
WEDNESDAY
Session III Sensory and psychological effects of
nicotine
Little attention has been focussed on the specific
sensory properties of nicotine and their influence
on the
smoking process. Research to identify and develop
our
knowledge in this area needs to be established and
will be
discussed. The ability to modify the sensory
effects of
nicotine by physical and chemical means has
important
implications for product design and acceptability.
The role of smoking as a psychological tool for
use as a
coping strategy for smokers during social
interaction and as
a life skill is of importance for the industry.
The experimental
approach to characterise this role including
current results
will be presented.
The primary objectives of the presentations and
group
discussions:
1. The research effort to characterise the sensory
properties
of nicotine is inadequate : can a productive
research
programme be developed at this time.
2. To critically examine whe~t*er the techniques
for assessing
the subjective properties of nicotine are
adequate.
3. To identify if nicotine protonation
mahipulation can be
used to modify and improve product quality.
4. To assess the psychological research programme
and assess
its capability of identifying the specific role of
smoking (and nicotine) as a coping strategy.
cy"
CO
'-C,
BATCo document for Province of British Columbia 5
November 1999


-4-
THURSDAY
Session IV Effects of Nicotine - Interaction with
the Brain
("Pharmacology")
Considerable indirect evidence has been
accumulated that
suggests inhaling cigarette smokers smoke for
nicotine and
presumably the pharmacological effects of
nicotine. Debate
exists, however, as to whether this is the
motivation for
smoke inhalation or simply the consequence of this
process.
The objective of this session will be to present
the research
activities that provide the fundamental base on
which to
develop and extend the research programme to
elucidate the
pharmacological properties of nicotine with a view
to future
product development.
The primary objectives of the presentations and
group
discussions:
1. To evaluate the potential to determine the
relationship
between the tissue distribution and concentration
of
nicotine in relation to its pharmacological
properties.
2. To identify if current techniques exist to
determine the
specific location of nicotine interaction within
the
brain and to examine the extent to which this
would
advance our understanding of the pharmacological
role of
nicotine.
3. To identify the specific direction of research
required
to determine the pharmacological properties of
nicotine.
BATCo document for Province of BritiSh Columbia 5
November 1999


-5-
THURSDAY
Session V Effects of Nicotine - Interaction with
peripheral
tissues ("Physiology")
This session concentrates on the ability of
nicotine to
interact within the respiratory tract and the
whole body to
elicit physiological and biochemical responses.
The significance
of these responses in terms of product assessment,
quality
and acceptability will be examined and the
research effort
required to characterise these events will be
identified.
The primary objectives of the presentations and
group
discussions:
1. Evaluate whether the physiological responses
are an
essential part of smoker satisfaction.
2. There is a need to characterise the
physiological changes
occurring under naturalistic smoking conditions :
can
the technical problems of this approach be
overcome?
3. To what extent can the knowledge of the upper
respiratory
tract responses be used to improve product
attributes.
4. To present the research direction and
development required
to modify and identify the relationship between
particle
size and concentration effects of either smoke or
synthetic aerosols and to establish wh*at
relevance these
approaches have for product design.
BATCo document for Province of British Columbia 5
November 1999


-6-
FRIDAY
Session VI Product Modification for maximal
nicotine effects
To suggest that products can be modified to
maximise
nicotine effects, assumes that we understand what
constitutes
an adequate and suitably 'packaged' dose of
nicotine to
satisfy a smokers 'requirements'. The extent to
which we
understand these requirements will be examined and
will
attempt to incorporate and summarise the
conference view.
The primary objectives of the presentations and
group
discussions:
1. To identify the current level of understanding
and the
extent to which nicotine contributes to product
satisfaction.
2. To what extent is it possible to determine the
significance
of the different levels of nicotine interaction
with the
body to smoking behaviour and product
satisfaction.
3. To present and identify a research programme to
meet the
criteria for maximising nicotine effects to
satisfy
consumer needs from a minimum dose of nicotine.
CzD
rl-
BATCO document for Province of British Columbia 5
November 1999


FRIDAY
Session VII General Session
A general discussion session to identify
additional
areas of interest relating to nicotine, followed
by discussions
to examine the objectives of each session and to
critically
assess the extent to which they satisfy the
current and future
research needs.
The primary objective of the group discussion to
be:
To identify the strengths, weaknesses and future
direction of research into the role of nicotine in
the smoking process.
411
C=)
BATCo document for Province of British Columbia 5
November 1999


NICOTINE CONFERENCE DELEGATE LIST
GR&DC
Dr. I. Ayres
Dr. M. Dixon
Dr. P. Godden
Dr. K. Kilburn
Mr. G. Read
Mr. R. Richardson
Dr. W. Templeton
Dr. M. Weaver
B&W
Mr. M.L. Reynolds
Dr. R.A. Sanford
BAT Hamburg
Dr. H. Barkemeyer
Dr. W. Hauser
Dr. A. Rudolph
ITL Canada
Dr. S.R. Massey
Mrs. C. McBride
Souza Cruz
Dr. I. Pedro
WD&HO Wills (Australia) Ltd.
Mr. T. Wilson
CD
BATCo document for Province of British Columbia 5
November 1999